Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

The U.S. Food and Drug Administration and the pharmaceutical company Novo Nordisk are urging consumers to be on the lookout ...

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results ...

A unique Novo Nordisk legal challenge to the Medicare drug pricing program could have big implications for the pharma ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind the groundbreaking GLP-1 weight loss drugs Ozempic and Wegovy, have been absolutely plummeting. The company's stock price slid over ...

Weight loss leader Novo Nordisk has had a poor performance at the stock markets year-to-date [YTD] even as the healthcare sector is among the least impacted ones. The key reason for this is ...

Analyst downgrades Novo Nordisk, cuts price target to $64. The analyst highlights that Lilly's drugs, Mounjaro and Zepbound, will gain U.S. market share from Novo Nordisk's Ozempic and Wegovy.

Novo Nordisk (NVO) has become aware of several hundred units of Ozempic injection 1 mg distributed outside the Novo Nordisk authorized supply chain in the U.S., the company announced. The Food and ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral weight-loss drug news and BMO cut its rating for the Danish drug developer ...

https://www.tipranks.com/news/the-fly/novo-nordisk-warns-of-counterfeit-ozempic-injections Novo Nordisk (NVO) said it has become aware of several hundred units of ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ thesis on NVO. Novo Nordisk A/S (NVO)'s share was trading at $64.49 ...